• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low

    1/19/23 10:13:25 AM ET
    $BEKE
    $CNCE
    $DCPH
    $GRRR
    Real Estate
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BEKE alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday.

    Following the market opening Thursday, the Dow traded down 0.62% to 33,090.82 while the NASDAQ fell 0.70% to 10,880.01. The S&P 500 also fell, dropping, 0.64% to 3,903.72.
    Check This Out: Ethereum Drops Below This Key Level; Gala Becomes Top Loser


    Leading and Lagging Sectors

    • Real estate shares rose by 0.5% on Thursday. Meanwhile, top gainers in the sector included The Real Brokerage Inc. (NASDAQ:REAX), up 6%, and KE Holdings Inc. (NYSE:BEKE), up 2%.
    • In trading on Thursday, financials shares dipped by 1.4%.


    Top Headline

    US initial jobless claims dropped by 15,000 from the prior week to 190,000 in the week ending January 14, the lowest in four months. However, analysts were expecting claims to reach 214,000.


    Equities Trading UP

    • Gorilla Technology Group Inc. (NASDAQ:GRRR) shares shot up 64% to $9.15. - Gorilla Technology Group completed the acquisition of the tech stack of SeeQuestor Limited.
    • Shares of RenovoRx, Inc. (NASDAQ:RNXT) got a boost, shooting 14% to $4.16. RenovoRx, on Wednesday, announced initial results from a pharmacokinetic (PK) substudy within the phase 3 un-blinded randomized control TIGeR-PaC clinical trial to be presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium this week.
    • Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares were also up, gaining 20% to $8.27 after Sun Pharma announced it will acquire the company.

     

    Equities Trading DOWN

    • Surmodics, Inc. (NASDAQ:SRDX) shares tumbled 24% to $28.30 after the company received a letter from the FDA related to its premarket approval (PMA) application for the SurVeil drug-coated balloon (DCB). In the letter, the FDA indicated that the application is not currently approvable while providing specific guidance on a path forward..
    • Shares of Olink Holding AB (NASDAQ:OLK) were down 17% to $19.98 after the company announced pricing of a public offering of American Depository Shares.
    • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) was down, falling 14% to $17.69 after the company announced a $125 million proposed public offering of common stock.

    Also Check This Out: Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying


    Commodities

    In commodity news, oil traded up 0.5% to $79.87 while gold traded up 0.6% at $1,917.80.

    Silver traded up 0.1% to $23.66 on Thursday while copper fell 0.2% to $4.2255.

    Stocks of crude oil in the US rose by 7.615 million barrels in the latest week, the American Petroleum Institute said Wednesday.

     

    Euro zone

    European shares were lower today. The eurozone’s STOXX 600 dropped 1.4%, London’s FTSE 100 fell 1% while Spain’s IBEX 35 Index fell 1.8%. The German DAX declined 1.5% French CAC 40 dropped 1.7% and Italy’s FTSE MIB Index fell 1.4%.

    The current account surplus in the Eurozone narrowed to EUR 13.4 billion in November compared to EUR 13.8 billion in the year-ago month. Spanish trade deficit narrowed to EUR 3.31 billion in November from EUR 4.21 billion in the year-ago month.

     

    Asia Pacific Markets

    Asian markets closed mostly lower on Thursday, with the Hong Kong’s Hang Seng Index falling 0.12%, and China’s Shanghai Composite Index rising 0.49%. Japan’s Nikkei 225 dropped 1.44%.

    Japan recorded a trade deficit of JPY 1,448.5 billion in December, wider from JPY 603.1 billion in the year-ago period. Hong Kong’s unemployment rate dropped to 3.5% during the three months ending December 2022, versus 3.7% in the prior September-November period. The unemployment rate in Australia came in steady at 3.5% in December.

     

    Economics

    • US initial jobless claims dropped by 15,000 from the prior week to 190,000 in the week ending January 14, the lowest in four months. However, analysts were expecting claims to reach 214,000.

    • Housing starts in the US fell 1.4% to an annualized rate of 1.382 million in December.

    • Building permits declined 1.6% from a month ago to an annual rate of 1.33 million in December.

    • The Philadelphia Fed Manufacturing Index increased to -8.9 in January versus a revised reading of -13.7 in the previous month.

    Now Read This: Investor Optimism Declines As Nasdaq Snaps 7-Day Win Streak


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 103,701,160 cases with around 1,127,050 deaths. India confirmed a total of at least 44,681,880 cases and 530,720 deaths, while France reported over 39,467,280 COVID-19 cases with 163,640 deaths. In total, there were at least 672,336,840 cases of COVID-19 worldwide with more than 6,736,630 deaths.

    Get the next $BEKE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEKE
    $CNCE
    $DCPH
    $GRRR

    CompanyDatePrice TargetRatingAnalyst
    KE Holdings Inc
    $BEKE
    2/3/2026$19.00Buy → Neutral
    Goldman
    Gorilla Technology Group Inc.
    $GRRR
    12/11/2025$31.00Overweight
    Cantor Fitzgerald
    Surmodics Inc.
    $SRDX
    11/14/2025Mkt Perform → Underperform
    Barrington Research
    KE Holdings Inc
    $BEKE
    10/31/2025$19.00Buy → Neutral
    UBS
    The Real Brokerage Inc.
    $REAX
    6/25/2025$7.00Buy
    B. Riley Securities
    KE Holdings Inc
    $BEKE
    5/16/2025$23.00Neutral → Buy
    UBS
    KE Holdings Inc
    $BEKE
    3/20/2025$22.70 → $24.50Buy → Neutral
    UBS
    Surmodics Inc.
    $SRDX
    3/7/2025$43.00Hold → Buy
    Lake Street
    More analyst ratings

    $BEKE
    $CNCE
    $DCPH
    $GRRR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KE Holdings downgraded by Goldman with a new price target

    Goldman downgraded KE Holdings from Buy to Neutral and set a new price target of $19.00

    2/3/26 6:53:05 AM ET
    $BEKE
    Real Estate
    Finance

    Cantor Fitzgerald initiated coverage on Gorilla Technology Group with a new price target

    Cantor Fitzgerald initiated coverage of Gorilla Technology Group with a rating of Overweight and set a new price target of $31.00

    12/11/25 9:09:09 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Surmodics downgraded by Barrington Research

    Barrington Research downgraded Surmodics from Mkt Perform to Underperform

    11/14/25 11:19:52 AM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    $BEKE
    $CNCE
    $DCPH
    $GRRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $169 worth of shares (205 units at $0.83), increasing direct ownership by 0.03% to 778,665 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/2/26 5:00:20 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEKE
    $CNCE
    $DCPH
    $GRRR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Real Brokerage Announces That Agent Leader Ken Pozek Has Joined Its Board of Directors

    Appointment reinforces Real's commitment to agent representation and long-term shared success The Real Brokerage Inc. (NASDAQ:REAX), a leading real estate technology platform redefining the industry through innovation and culture, today announced that agent leader Ken Pozek, founder and leader of The Pozek Group, has joined the Company's Board of Directors. The appointment reflects Real's belief that its agents, who collectively represent the company's largest shareholder group, should have a direct voice in shaping its strategic direction. "As a brokerage built by and for agents, it's important that their perspective is represented in the boardroom," said Tamir Poleg, Chairman and CEO

    2/11/26 7:30:00 AM ET
    $REAX
    Real Estate
    Finance

    RenovoRx Establishes RenovoCath® Medical Advisory Board

    MOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the formation of a dedicated RenovoCath Medical Advisory Board ("MAB") to support its clinical and strategic initiatives. The MAB brings together leading US interventional radiology experts to provide strategic clinical insights that further advance the TAMP (Trans-Arterial Micro-Perfusion) therapy platform in clinical indications of high unmet medical need. The MAB compliments the Company's esteemed and lon

    2/10/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEKE
    $CNCE
    $DCPH
    $GRRR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $169 worth of shares (205 units at $0.83), increasing direct ownership by 0.03% to 778,665 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/2/26 5:00:20 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEKE
    $CNCE
    $DCPH
    $GRRR
    SEC Filings

    View All

    SEC Form 6-K filed by The Real Brokerage Inc.

    6-K - Real Brokerage Inc (0001862461) (Filer)

    2/11/26 9:59:12 AM ET
    $REAX
    Real Estate
    Finance

    RenovoRx Inc. filed SEC Form 8-K: Other Events

    8-K - RenovoRx, Inc. (0001574094) (Filer)

    2/6/26 7:00:43 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by KE Holdings Inc

    6-K - KE Holdings Inc. (0001809587) (Filer)

    2/6/26 6:01:43 AM ET
    $BEKE
    Real Estate
    Finance

    $BEKE
    $CNCE
    $DCPH
    $GRRR
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Real Expands Michigan Footprint as Jim Shaffer and 172-Agent Brokerage Good Company Join Through Private Label Program

    Independent brokerage joins Real through the Private Label program, bringing 1,900 home sales valued at $500 million in 2025 The Real Brokerage Inc. (NASDAQ:REAX), a leading real estate technology platform redefining the industry through innovation and culture, today announced that Michigan real estate leader Jim Shaffer and his independent brokerage, Good Company, have joined Real through its Private Label program. Based in Royal Oak, Mich., Good Company brings 172 agents to Real, including Shaffer's 40-agent team, further strengthening Real's presence across the Detroit metropolitan area. Founded in 2020 by Shaffer and his sister, Gina Jones, Good Company has experienced rapid growth

    1/13/26 7:30:00 AM ET
    $REAX
    Real Estate
    Finance

    Sandy MacKay Brings Found Spaces Realty Group and Network of 50 Top Ontario Agents to Real

    Real strengthens its Ontario presence with one of Canada's best-known real estate leaders and a high-performing network of agents with more than $500 million in annual sales The Real Brokerage Inc. (NASDAQ:REAX), a leading real estate technology platform redefining the industry through innovation and culture, today announced that Sandy MacKay, one of Canada's most respected team leaders and real estate investment experts, has brought his 12-agent Found Spaces Realty Group team, averaging $100 million in volume per year over the past eight years, as well as a network of 50 additional top-producing agents across Ontario with $500 million in annual sales to Real. With 15 years of real estate

    12/18/25 7:30:00 AM ET
    $REAX
    Real Estate
    Finance

    $BEKE
    $CNCE
    $DCPH
    $GRRR
    Financials

    Live finance-specific insights

    View All

    The Real Brokerage to Host Fourth Quarter and Full Year 2025 Earnings Conference Call

    The Real Brokerage Inc. (NASDAQ:REAX), a leading real estate technology platform redefining the industry through innovation and culture, will release its financial results for the fourth quarter and full year ended December 31, 2025, on Wednesday, March 4, 2026, before the market opens. The Company will hold a conference call to discuss operating and financial results for the quarter at 8:00 a.m. ET on Wednesday, March 4, 2026. Investors wishing to join the live call can use the dial-in details provided below. An audio-only webcast of the call will be available on the Investor Relations section of the Company's website at https://investors.onereal.com/ and can also be accessed directly th

    1/26/26 8:00:00 AM ET
    $REAX
    Real Estate
    Finance

    RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

    September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (NASDAQ:RNXT) ("RenovoRx" or the "Company"), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced its financial results and provided a business update to shareholders for the third quarter ended September 30, 2025. "We continue to make strong progress both in our commercial and clinical activities," said Shaun Bagai, CEO of

    11/13/25 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gorilla Technology to Host Q3 2025 Financial Results Conference Call on November 18 at 8:30 a.m. ET

    London, United Kingdom--(Newsfile Corp. - November 12, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company") will hold a conference call on Tuesday, November 18, 2025, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time) to discuss its financial results for the three months ended September 30, 2025. Financial results will be issued in a press release before the call.Call Date: Tuesday, November 18, 2025 Time: 8:30 a.m. Eastern time (5:30 a.m. Pacific time) Toll Free: +1-800-715-9871International: +1-647-932-3411Conference ID: 8417220Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

    11/12/25 9:00:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    $BEKE
    $CNCE
    $DCPH
    $GRRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    12/6/24 9:25:12 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Surmodics Inc.

    SC 13G/A - SURMODICS INC (0000924717) (Subject)

    11/14/24 3:36:00 PM ET
    $SRDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by The Real Brokerage Inc.

    SC 13G/A - Real Brokerage Inc (0001862461) (Subject)

    11/12/24 8:41:29 PM ET
    $REAX
    Real Estate
    Finance